Xing-xing Chen1, Jiang Lin2, Jun Qian3, Wei Qian2, Jing Yang1, Ji-chun Ma2, Zhao-qun Deng2, Dong Xie4, Cui An1, Chun-yan Tang1, Zhen Qian1. 1. Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China. 2. Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China. 3. Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China. Electronic address: qianjun0007@hotmail.com. 4. Laboratory of Molecular Oncology, Institute for Nutritional Sciences, Shanghai Institutes of Biological Sciences, Shanghai, People's Republic of China.
Abstract
OBJECTIVE: MicroRNA miR-124 has been suggested as a tumor suppressor for its role in inhibiting cell growth, inducing differentiation and promoting apoptosis. The present study was aimed to investigate the expression status of miR-124-1 and its clinical relevance in patients with acute myeloid leukemia (AML). DESIGNS AND METHODS: Real-time quantitative PCR was performed to detect the expression level of miR-124-1 in AML patients. The clinical significance of miR-124-1 expression in AML was investigated. RESULTS: miR-124-1 underexpression was identified in 30 (36%) of 83 AML patients. No significant difference could be observed in sex, age and blood parameters between the patients with and without miR-124-1 underexpression. The frequency of miR-124-1 underexpression was higher in the patients with t(15;17) than in others (62% versus 30%, P = 0.040). The status of miR-124-1 expression was not correlated with the mutations of nine genes (FLT3-ITD, NPM1, C-KIT, IDH1/IDH2, DNMT3A, N/K-RAS and C/EBPA). The patients with miR-124-1 underexpression had borderline longer overall survival and relapse-free survival than those without miR-124-1 underexpression (P = 0.052 and 0.045, respectively). CONCLUSIONS: These findings suggest that miR-124-1 underexpression is a common event and might have a favorable impact on prognosis in AML.
OBJECTIVE: MicroRNA miR-124 has been suggested as a tumor suppressor for its role in inhibiting cell growth, inducing differentiation and promoting apoptosis. The present study was aimed to investigate the expression status of miR-124-1 and its clinical relevance in patients with acute myeloid leukemia (AML). DESIGNS AND METHODS: Real-time quantitative PCR was performed to detect the expression level of miR-124-1 in AMLpatients. The clinical significance of miR-124-1 expression in AML was investigated. RESULTS:miR-124-1 underexpression was identified in 30 (36%) of 83 AMLpatients. No significant difference could be observed in sex, age and blood parameters between the patients with and without miR-124-1 underexpression. The frequency of miR-124-1 underexpression was higher in the patients with t(15;17) than in others (62% versus 30%, P = 0.040). The status of miR-124-1 expression was not correlated with the mutations of nine genes (FLT3-ITD, NPM1, C-KIT, IDH1/IDH2, DNMT3A, N/K-RAS and C/EBPA). The patients with miR-124-1 underexpression had borderline longer overall survival and relapse-free survival than those without miR-124-1 underexpression (P = 0.052 and 0.045, respectively). CONCLUSIONS: These findings suggest that miR-124-1 underexpression is a common event and might have a favorable impact on prognosis in AML.
Authors: Oxana Dobrovinskaya; Georgina Valencia-Cruz; Luis Castro-Sánchez; Edgar O Bonales-Alatorre; Liliana Liñan-Rico; Igor Pottosin Journal: Front Pharmacol Date: 2016-08-31 Impact factor: 5.810